Benjamin Graham Detailed Fundamental Analysis

Validea's guru fundamental report identifies Regeneron Pharmaceuticals (REGN) as its highest-rated stock under the Benjamin Graham Value Investor model, achieving a 71% score. While the large-cap biotech passes key fundamental criteria such as sales, current ratio, debt, and long-term EPS growth, it fails the model's strict P/E and Price/Book ratio valuation tests. This suggests that despite strong underlying business health, REGN's current valuation limits its appeal as a deep value investment according to this specific methodology.

Analysis

Regeneron Pharmaceuticals (REGN) exhibits a dichotomous profile according to a Validea analysis based on Benjamin Graham's deep value methodology. The company scores a respectable but not compelling 71%, falling short of the 80-90% range that typically signals strong interest from this value-oriented strategy. Fundamentally, REGN demonstrates significant strength, passing crucial tests for sales performance, current ratio, and long-term EPS growth. Furthermore, its balance sheet appears robust, as indicated by its low long-term debt relative to net current assets. However, the company fails on the two key valuation metrics central to the Graham model: its Price-to-Earnings (P/E) and Price-to-Book (P/B) ratios are too high to meet the strict criteria for a deep value investment. This suggests that while REGN is a fundamentally sound, large-cap growth company, its current market valuation reflects this quality and does not offer the margin of safety sought by traditional Graham-style value investors.

Key Decisions for Investors

• Deep value investors adhering to strict Graham principles should approach with caution, as REGN's current valuation on P/E and P/B metrics explicitly fails the model's criteria despite strong underlying fundamentals.
• Investors with a growth or 'Growth at a Reasonable Price' (GARP) mandate may view the positive fundamental signals, such as strong long-term EPS growth and low debt, as justification for the premium valuation.
• Monitor for any deceleration in sales or EPS growth, as the current valuation is heavily dependent on these metrics continuing to outperform, making the stock vulnerable to a correction if growth falters.